Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
AIM Vaccine Co Ltd
Akshaya Bio Inc
Beijing Zhifei Lvzhu Biopharmaceutical Co Ltd
Changchun Bcht Biotechnology Co Ltd
Chi tiol Pharmaceutical Group Corp
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
EyeGene Inc
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
Jiangsu Rec-Biotechnology Co Ltd
L Pharmaceuticals Ltd
noViricides Inc
Shulov Innovative Science Ltd
Vaccitech plc
Vapogenix Inc
XBiotech Inc
Herpes Zoster (Shingles) - Drug Profiles
B-1006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVIVZV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-HZ - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-3220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shingles vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varicella zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Mar 30, 2021: Curevo Vaccine announces the approval to conduct a phase 1b clinical trial in South Africa to evaluate safety and immunogenicity of its adjuvanted subunit investigatiol vaccine, CRV-101, against varicella (Chickenpox) in HIV-positive children
Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigatiol vaccine for Shingles CRV-101
Jul 23, 2020: CHMP recommended extension of indication for Shingrix
May 14, 2020: noViricides provides update on drug candidate NV-HHV-101
Mar 10, 2020: First QS-21 royalty payment due to Agenus is triggered
Jan 09, 2020: noViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
Jan 07, 2020: noViricides has initiated genetic toxicology testing required for an IND for its drug candidate
Dec 06, 2019: noViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
Dec 03, 2019: noViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
Dec 02, 2019: noViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
Nov 19, 2019: noViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind ebling studies update, progressing towards clinical trials
Oct 31, 2019: noViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
Oct 09, 2019: noViricides has initiated bio-alytical studies as part of IND-ebling safety and toxicology studies of lead candidate NV-HHV-101
Oct 03, 2019: noViricides is creating nomedicines to develop antiviral therapies to combat shingles and herpes viruses
Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Herpes Zoster (Shingles), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Herpes Zoster (Shingles), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Herpes Zoster (Shingles) - Pipeline by AIM Vaccine Co Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by Akshaya Bio Inc, 2021
Herpes Zoster (Shingles) - Pipeline by Beijing Zhifei Lvzhu Biopharmaceutical Co Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by China National Pharmaceutical Group Corp, 2021
Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by EyeGene Inc, 2021
Herpes Zoster (Shingles) - Pipeline by GC Pharma, 2021
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, 2021
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, 2021
Herpes Zoster (Shingles) - Pipeline by Jiangsu Rec-Biotechnology Co Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, 2021
Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, 2021
Herpes Zoster (Shingles) - Pipeline by Vaccitech plc, 2021
Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, 2021
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, 2021
Herpes Zoster (Shingles) - Dormant Projects, 2021
Herpes Zoster (Shingles) - Discontinued Products, 2021